Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Control of spiral breakup by an alternating advective field.

The Journal of chemical physics·2006

Same author

Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.

Clinical cancer research : an official journal of the American Association for Cancer Research·2006

Same author

New rod-plate anterior instrumentation for thoracolumbar/lumbar scoliosis: biomechanical evaluation compared with dual-rod and single-rod with structural interbody support.

Spine·2006

Same author

Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.

International journal of cancer·2006

Same author

A unified mode of epigenetic gene silencing: RNA meets polycomb group proteins.

RNA biology·2006

Same author

Molecular signaling and genetic pathways of senescence: Its role in tumorigenesis and aging.

Journal of cellular physiology·2006

Search research articles

Related Experiment Video

Updated: May 31, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Anti-IL-1β therapies.

¹Women's Hospital and Department of Biomedicine, University of Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland. hzhang@uhbs.ch

Recent Patents on DNA & Gene Sequences

|July 19, 2011

Summary

Interleukin-1 beta (IL-1β) is key in inflammatory diseases and is activated by inflammasomes. Patenting inflammasome research is paving the way for novel anti-inflammatory therapies.

Area of Science:

Immunology
Pharmacology
Biochemistry

Background:

Interleukin-1 beta (IL-1β) is a major cytokine driving inflammatory diseases.
Inflammasomes activate IL-1β upon sensing danger signals, highlighting their role in pathogenesis.
IL-1β is a significant target for developing new anti-inflammatory drugs.

Purpose of the Study:

To review current patent landscapes concerning IL-1β blockade strategies.
To explore the therapeutic potential of targeting inflammasomes for inflammatory conditions.
To forecast future patenting trends in inflammasome research and drug development.

Main Methods:

Analysis of existing patents focusing on IL-1β inhibitors.
Review of approved and investigational IL-1β targeting agents.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Related Experiment Videos

Last Updated: May 31, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Examination of the role of inflammasomes in disease and therapeutic intervention.

Main Results:

Patents primarily cover methods and applications of four IL-1β blockade types: antibodies, IL-1 receptor antagonists (sIL-1Ra, icIL-1Ra), and IL-1 traps.
Rilonacept and canakinumab are FDA-approved, with other agents showing promise in clinical trials.
Significant patent activity exists, reflecting the therapeutic interest in IL-1β pathways.

Conclusions:

The patent landscape indicates robust development in IL-1β targeted therapies.
Approved and investigational drugs demonstrate the clinical viability of IL-1β blockade.
Future patents in inflammasome research are expected to drive innovation in anti-inflammatory treatments.